| [1]Bernard Y-H.Epidemiology and risk factors for drug allergy[J].Br J Clin Pharmacol, 2011, 71(5):684-700[2]Halevy S.Acute generalized exanthematous pustulosis[J].Curr Opin Allergy Clin Immunol, 2009, 9(4):322-328[3]Clavenna A, Bonati M.Adverse drug reactions in childhood:a review of prospective studies and safety alerts[J].Arch Dis Child, 2009, 94(9):724-728[4] Gamboa PM.The epidemiology of drug allergy-related consultations in Spanish Allergology Services:Alergológica-2005[J]. J Investig Allergol Clin Immunol, 2009, 19 Suppl 2: 45–50.[5]Budnitz DS, Pollock DA, Weidenbach KN, et al.National surveillance of emergency department visits for outpatient adverse drug events[J].JAMA, 2006, 296(15):1858-1866[6]Cohen AL, Budnitz DS, Weidenbach KN, et al.National surveillance of emergency department visits for outpatient adverse drug events in children and adolescents[J].J Pediatr, 2008, 152(3):416-421[7]Dantonio C, Galimberti M, Barbone B, et al.Suspected acute allergic reactions: analysis of admissions to the Emergency Department of the AOU Maggiore della Carit Hospital in Novara from 2003 to 2007[J].Eur Ann Allergy Clin Immunol, 2008, 40(4):122-129[8]Borchers AT, Lee JL, Naguwa SM, et al.Stevens-Johnson syndrome and toxic epidermal necrolysis[J].Autoimmun Rev, 2008, 7(8):598-605[9]Kim HJ, Jung KD, Lee KT, et al.Acute Generalized Exanthematous Pustulosis Caused by Diltiazem[J].Ann Dermatol, 2011, 23(1):108-110[10] Izquierdo JH, Bonilla-Abadía F, Ochoa CD, et al.Acute Generalized Exanthematous Pustulosis due to Tocilizumab in a Rheumatoid Arthritis Patient[J]. Case Rep Rheumatol, 2012:517424.[11]Liquete E, Ali S, Kammo R, et al.Acute generalized exanthematous pustulosis induced by erlotinib (tarceva) with superimposed staphylococcus aureus skin infection in a pancreatic cancer patient: a case report[J].Case Rep Oncol, 2012, 5(2):253-259[12]Li LF, Ma C.Epidemiological study of severe cutaneous adverse drug reactions in a city district of China[J].Clin Exp Dermatol, 2006, 31(5):642-647[13]Ozeki T, Mushiroda T, Yowang A, et al.Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population[J].Hum Mol Genet, 2011, 20(5):1034-1041[14]Hashizume H.Recent progress of elucidating the mechanisms of drug hypersensitivity[J].Asia Pac Allergy, 2012, 2(3):203-209[15]Annunziato F, Romagnani S.Heterogeneity of human effector CD4+T cells[J].Arthritis Res Ther, 2009, 11(6):257-[16]Morel E, Escamochero S, Caba?as R, et al.CD94NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis[J].J Allergy Clin Immunol, 2010, 125(3):703-710[17]Romagnani S.Human Th17 cells[J].Arthritis Res Ther, 2008, 10(2):206-[18]Takahashi R, Kano Y, Yamazaki Y, et al.Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome[J].J Immunol, 2009, 182(12):8071-8079[19] Piccinini AM, Midwood KS.DAMPening inflammation by modulating TLR signalling[J]. Mediators Inflamm, 2010:672395.[20]Bellón T, Alvarez L, Mayorga C, et al.Differential gene expression in drug hypersensitivity reactions: induction of alarmins in severe bullous diseases[J].Br J Dermatol, 2010, 162(5):1014-1022[21]Nakajima S, Watanabe H, Tohyama M, et al.High-mobility group box 1 protein (HMGB1) as a novel diagnostic tool for toxic epidermal necrolysis and Stevens-Johnson syndrome[J].Arch Dermatol, 2011, 147(9):1110-1112[22]Clayberger C, Finn MW, Wang T, et al.kDa granulysin causes differentiation of monocytes to dendritic cells but lacks cytotoxic activity[J].J Immunol, 2012, 188(12):6119-6126[23]Tewary P, Yang D, de la Rosa G, et al.Granulysin activates antigen-presenting cells through TLR4 and acts as an immune alarmin[J].Blood, 2010, 116(18):3465-3474[24]Hetherington S, Hughes AR, Mosteller M, et al.Genetic variations in HLA-B region and hypersensitivity reactions to abacavir[J].Lancet, 2002, 359(9312):1121-1122[25]Mallal S, Nolan D, Witt C, et al.Association between presence of HLA-B*5701,HLA-DR7,and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir[J].Lancet, 2002, 359(9308):727-732[26]Chung WH, Hung SI, Hong HS, et al.Medical genetics: A marker for Stevens–Johnson syndrome[J].Nature, 2004, 428(6982):486-[27]Wang H, Yan L, Zhang G, et al.Association between HLA-B*1301 and Dapsone-Induced Hypersensitivity Reactions among Leprosy Patients in China[J].J Invest Dermatol, 2013, 133(11):2642-2644 |
